Back to Search
Start Over
Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
- Source :
-
Clinical breast cancer [Clin Breast Cancer] 2019 Aug; Vol. 19 (4), pp. 304-310. Date of Electronic Publication: 2019 Feb 06. - Publication Year :
- 2019
-
Abstract
- Background: Of women diagnosed with metastatic breast cancer (MBC), 20% to 30% survive ≥5 years. We evaluated data from a large breast cancer program to identify features associated with MBC survival.<br />Patients and Methods: Women diagnosed with MBC in or after 1999 were included. Long-term MBC survival was defined as ≥5 years from date of MBC diagnosis (n = 122), short-term MBC survival as ≤2 years (n = 191). Differences were assessed using t tests, Wilcoxon-Mann-Whitney tests, χ <superscript>2</superscript> , and Fisher exact tests. Odds ratios (ORs) were calculated using multivariate logistic regression models.<br />Results: Long-term survivors were significantly (P < .05) younger, premenopausal, partnered, had estrogen receptor (ER)-positive, progesterone receptor-positive, and HER2-positive disease, lower Charlson Comorbidity Index, lower rates of visceral metastases, and higher household income. After adjustment for potential confounders, de novo MBC, premenopausal status, ER-positive status, and HER2-positive status remained significantly positively associated with long-term survival (respectively: OR, 2.68 [95% confidence interval (CI), 1.48-4.88]; OR, 1.96 [95% CI, 1.02-3.79]; OR, 3.74 [95% CI, 1.72-8.14]; OR, 2.88 [95% CI, 1.61-5.14]). Triple-negative status, visceral with bone metastases, and brain metastases remained negatively associated with long-term survival (respectively: OR, 0.12 [95% CI, 0.05-0.29]; OR, 0.18 [95% CI, 0.07-0.47]; OR, 0.16 [95% CI, 0.04-0.60]). Partner status and household income were significant in univariate but not multivariate analyses.<br />Conclusion: Diagnosis of de novo MBC, premenopausal status, ER-positive status, and HER2-positive status were positively associated whereas triple-negative status, brain metastases, and visceral with bone metastases were inversely associated with long-term survival. These findings can be applied to better prognosticate survival for MBC patients.<br /> (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Subjects :
- Bone Neoplasms drug therapy
Bone Neoplasms metabolism
Bone Neoplasms secondary
Brain Neoplasms drug therapy
Brain Neoplasms metabolism
Brain Neoplasms secondary
Breast Neoplasms drug therapy
Breast Neoplasms metabolism
Breast Neoplasms pathology
Carcinoma, Ductal, Breast drug therapy
Carcinoma, Ductal, Breast metabolism
Carcinoma, Ductal, Breast mortality
Carcinoma, Ductal, Breast secondary
Carcinoma, Lobular drug therapy
Carcinoma, Lobular metabolism
Carcinoma, Lobular mortality
Carcinoma, Lobular secondary
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Neoplasm Invasiveness
Prognosis
Receptor, ErbB-2 metabolism
Receptors, Estrogen metabolism
Receptors, Progesterone metabolism
Retrospective Studies
Survival Rate
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bone Neoplasms mortality
Brain Neoplasms mortality
Breast Neoplasms mortality
Survivors statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0666
- Volume :
- 19
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinical breast cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30827763
- Full Text :
- https://doi.org/10.1016/j.clbc.2019.01.014